Sugi Predict

Sugi Predict / Compounds / SCHEMBL929484

SCHEMBL929484

SCHEMBL929484

C[C@]1(F)[C@H](O)O[C@H](COC(=O)c2ccccc2)[C@H]1OC(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.50
▸ POLB P06746 2/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ GAA P10253 2/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HIF1A Q16665 1/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39
▸ SYNJ2 O15056 3/20 0.39
▸ HTT P42858 1/20 0.39
▸ LGALS9 O00182 1/20 0.39
▸ LGALS1 P09382 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19326429 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL1844446 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL15127206 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL1844450 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL13187913 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL19326334 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL1844448 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL18271833 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL17453216 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL2481853 0.88 UPP1 (0.47) ALDH1A1POLBGAANPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4526318-A1 FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST VIRUSES University of Maryland, Baltimore County (US) 2025-03-26 — — EP disclosed
US-20250092080-A1 FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST VIRUSES UNIVERSITY OF MARYLAND, BALTIMORE COUNTY 2025-03-20 — — US disclosed
WO-2023225042-A1 FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST VIRUSES UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) 2023-11-23 — — WO disclosed
EP-2755985-B1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS IDENIX PHARMACEUTICALS LLC (US) 2017-11-01 — — EP disclosed
EP-3222628-A1 NUCLEOSIDE PHOSPHORAMIDATES Gilead Pharmasset LLC (US) 2017-09-27 — — EP disclosed
EP-2752422-B1 Stereoselective synthesis of phosphorus containing actives GILEAD PHARMASSET LLC (US) 2017-08-16 — — EP disclosed
EP-2755983-B1 SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS IDENIX PHARMACEUTICALS LLC (US) 2017-03-15 — — EP disclosed
EP-2376088-B1 6-O-Substituted-2-amino-purine nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2017-02-22 — — EP disclosed
US-9416154-B2 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases MERCK SHARP & DOHME CORP. (US) 2016-08-16 — — US disclosed
US-9403863-B2 Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections IDENIX PHARMACEUTICALS LLC (US) 2016-08-02 — — US disclosed
US-20110015146-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2011-01-20 — — US disclosed
US-20110015146-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2011-01-20 — — US disclosed
US-20100286083-A1 NUCLEOSIDE ANALOGS PHARMASSET, INC. (US) 2010-11-11 — — US disclosed
US-20100286083-A1 NUCLEOSIDE ANALOGS PHARMASSET, INC. (US) 2010-11-11 — — US disclosed
US-20100279973-A1 SYNTHESIS OF PURINE NUCLEOSIDES PHARMASSET, INC. (US) 2010-11-04 — — US disclosed
WO-2010075554-A1 SYNTHESIS OF PURINE NUCLEOSIDES PHARMASSET, INC. (US) 2010-07-01 — — WO disclosed
WO-2010075549-A2 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2010-07-01 — — WO disclosed
WO-2010075549-A2 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2010-07-01 — — WO disclosed
US-20100081628-A1 NUCLEOSIDE CYCLICPHOSPHATES PHARMASSET, INC. (US) 2010-04-01 — — US disclosed
US-20100081628-A1 NUCLEOSIDE CYCLICPHOSPHATES PHARMASSET, INC. (US) 2010-04-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279973-A1 SYNTHESIS OF PURINE NUCLEOSIDES PNP, NUDT1, TYMP ALDH1A1 2131/4885POLB 266/4885MAPK1 1554/4885
US-20110015146-A1 NUCLEOSIDE PHOSPHORAMIDATES PNP, TYMP, NUDT14 ALDH1A1 2155/4885POLB 150/4885MAPK1 2126/4885
US-20250092080-A1 FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST VIRUSES FLNA, PNP, SMCHD1 ALDH1A1 4356/4885POLB 160/4885MAPK1 3502/4885
US-20100081628-A1 NUCLEOSIDE CYCLICPHOSPHATES PNP, NUDT1, TYMP ALDH1A1 3540/4885POLB 83/4885MAPK1 2665/4885
US-20100286083-A1 NUCLEOSIDE ANALOGS PNP, SAMHD1, HAVCR2 ALDH1A1 931/4885POLB 77/4885MAPK1 3774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.